Can CBD cause gynaecomastia? This is a question increasingly asked as CBD use grows across the UK. Gynaecomastia — the benign enlargement of glandular breast tissue in males — has several well-established causes, including hormonal imbalances, certain medications, and recreational substances such as cannabis. CBD (cannabidiol) is a non-intoxicating compound derived from Cannabis sativa, and whilst cannabis use has been associated with gynaecomastia in some case reports, CBD has a distinct pharmacological profile. This article examines the current evidence, explains how CBD interacts with hormonal pathways, and advises when to seek medical assessment.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an oestrogen-androgen imbalance; causes include hormonal changes, medications, recreational substances including cannabis, and medical conditions such as hypogonadism.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting in a noticeable swelling beneath one or both nipples. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular growth. Gynaecomastia is relatively common, affecting an estimated 30–60% of males at some point during their lifetime, with peaks occurring during infancy, puberty, and older adulthood.

The underlying cause is typically an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Even though males produce small amounts of oestrogen naturally, any shift that increases oestrogenic signalling — or reduces androgenic influence — can stimulate glandular growth. Common causes include:

• Hormonal changes during puberty or ageing

• Medications, including anabolic steroids, anti-androgens (e.g., spironolactone, finasteride, bicalutamide), certain antipsychotics, some antidepressants, cimetidine, ketoconazole, and some HIV therapies

• Recreational substances, such as cannabis, alcohol, and anabolic steroids

• Medical conditions, including hypogonadism, hyperthyroidism, liver cirrhosis, and renal failure

• Obesity, which increases peripheral conversion of androgens to oestrogens

In many cases, particularly in adolescents, gynaecomastia resolves spontaneously without treatment. However, persistent or painful breast tissue changes warrant clinical evaluation. Red-flag features that require prompt assessment include a hard, irregular, or fixed breast mass; skin changes such as peau d'orange; nipple retraction; blood-stained nipple discharge; and axillary lymphadenopathy — any of which may suggest male breast cancer rather than benign gynaecomastia.

NICE guidance (NG12: Suspected cancer: recognition and referral) recommends an urgent two-week-wait referral for males aged 30 and over with an unexplained breast lump, and urgent referral for males aged 50 and over with unilateral nipple changes (such as discharge, retraction, or other concerning features). Any unexplained breast change in a male patient should be assessed by a GP, who may refer to an endocrinologist or breast specialist depending on findings. Understanding the range of potential causes is essential before attributing gynaecomastia to any single substance, including cannabidiol (CBD).

How CBD Affects Hormones in the Body

CBD interacts with the endocannabinoid system, which regulates the HPG axis governing sex hormone production, but clinically meaningful hormonal effects in humans at standard supplemental doses have not been consistently demonstrated.

Cannabidiol (CBD) is a non-intoxicating phytocannabinoid derived from the Cannabis sativa plant — it does not cause a 'high'. Unlike tetrahydrocannabinol (THC), CBD does not bind directly to CB1 or CB2 cannabinoid receptors with high affinity. Instead, it exerts its effects through multiple pharmacological pathways, including modulation of the endocannabinoid system and interaction with serotonin (5-HT1A) receptors and transient receptor potential (TRP) channels. CBD has also been reported in some preclinical studies to inhibit fatty acid amide hydrolase (FAAH), though the relevance of this effect in humans at typical supplemental doses remains uncertain.

The endocannabinoid system plays a recognised role in regulating the hypothalamic-pituitary-gonadal (HPG) axis, which governs the production and release of sex hormones including testosterone, luteinising hormone (LH), and follicle-stimulating hormone (FSH). Preclinical studies — primarily conducted in animals — have suggested that cannabinoids can influence this axis, potentially suppressing LH pulses and reducing testosterone synthesis in Leydig cells of the testes.

It is important to note that most of this research has focused on THC rather than CBD specifically. The two compounds have distinct pharmacological profiles, and findings from THC studies cannot be directly extrapolated to CBD. Some laboratory research has suggested CBD may have weak effects on sex hormone pathways at certain concentrations, but these findings are largely preclinical and have not been consistently demonstrated in human clinical trials at doses typically used in commercially available products.

In summary, while CBD does interact with systems that influence hormonal regulation, the clinical significance of these interactions in humans — particularly at standard supplemental doses — remains poorly understood and should not be overstated without robust supporting evidence.

Is There a Link Between CBD and Gynaecomastia?

There is currently no established causal link between CBD and gynaecomastia; case reports associating cannabis with gynaecomastia typically involve high-THC products rather than isolated CBD.

The question of whether CBD can cause gynaecomastia has gained attention as CBD use has grown substantially in the UK following the classification of CBD extracts as novel foods, with the Food Standards Agency (FSA) overseeing their safety assessment since 2019. However, it is important to approach this question with scientific caution: there is currently no established or officially recognised causal link between CBD use and gynaecomastia.

The association between cannabis use and gynaecomastia has been discussed in medical literature for several decades, largely in the context of recreational cannabis containing significant levels of THC. THC has been proposed to interfere with the HPG axis and may suppress testosterone production. Some case reports have documented gynaecomastia in heavy cannabis users, though establishing direct causality is difficult given confounding factors such as concurrent substance use, nutritional status, and underlying health conditions. The precise mechanism by which THC might contribute to gynaecomastia remains incompletely understood, and claims about specific receptor interactions should be interpreted cautiously in the absence of robust human evidence.

CBD, by contrast, has a fundamentally different mechanism of action, and its influence on testosterone levels in humans has not been clearly demonstrated in well-designed clinical studies. That said, some individuals report breast tenderness or tissue changes whilst using CBD products, and these reports — while anecdotal — should not be entirely dismissed.

One important consideration is product quality and contamination. Many CBD products available in the UK may contain undisclosed levels of THC or other phytocannabinoids, which could theoretically contribute to hormonal effects. This underscores the importance of purchasing from reputable, third-party tested sources and checking Certificates of Analysis (CoA) from accredited laboratories.

What the Current Evidence and Research Shows

No randomised controlled trials have investigated CBD and gynaecomastia in humans, and neither the MHRA nor EMA list gynaecomastia as an adverse effect of pharmaceutical-grade CBD (Epidyolex).

The current body of evidence examining CBD's direct effect on male breast tissue or sex hormone levels in humans is limited. Most available data comes from preclinical (animal or cell-based) studies, which, whilst informative, do not reliably predict outcomes in human physiology at real-world doses.

A small number of human studies have examined CBD's effects on cortisol and anxiety-related hormones, but few have specifically measured testosterone, LH, FSH, or oestradiol levels in response to CBD supplementation. The only high-dose pharmaceutical-grade CBD product authorised in the UK is Epidyolex (cannabidiol oral solution), licensed for specific epilepsy indications. According to the MHRA-approved Summary of Product Characteristics (SmPC) and the EMA's European Public Assessment Report (EPAR) for Epidyolex, gynaecomastia is not listed as a recognised adverse effect, even at therapeutic doses substantially higher than those found in food supplements.

Key points from the current evidence base include:

• No randomised controlled trials have specifically investigated CBD and gynaecomastia in humans

• Animal studies suggest cannabinoids can modulate the HPG axis, but these findings are largely THC-specific

• Case reports linking cannabis to gynaecomastia typically involve high-THC products rather than isolated CBD

• The MHRA and EMA have not issued safety warnings specifically connecting CBD to gynaecomastia, and it is not listed as an adverse effect in the Epidyolex SmPC or EPAR

• The FSA's ongoing novel food authorisation process for CBD does not currently flag gynaecomastia as a safety concern

In the absence of robust human evidence, it would be premature to conclude that CBD causes gynaecomastia. However, the lack of evidence is not the same as evidence of safety, and further well-designed research is needed. Individuals who notice breast changes whilst using CBD should seek medical advice rather than self-diagnosing.

When to Speak to a GP About Breast Tissue Changes

Any male with a breast lump, nipple discharge, skin changes, or persistent breast tenderness should see a GP; NICE NG12 recommends urgent two-week-wait referral for males aged 30 and over with an unexplained breast lump.

Any male who notices changes in breast tissue — whether or not they are using CBD — should seek a medical assessment. Whilst gynaecomastia is often benign and self-limiting, it can occasionally be a sign of an underlying condition requiring treatment. Prompt evaluation helps to rule out more serious causes and provides reassurance where appropriate.

You should contact your GP if you experience:

• A lump or swelling beneath one or both nipples

• Breast tenderness or pain that is persistent or worsening

• Nipple discharge of any kind, particularly if blood-stained

• Asymmetrical breast changes or rapid growth of breast tissue

• Skin changes over the breast, such as dimpling or peau d'orange

• Breast changes accompanied by other symptoms, such as fatigue, weight changes, or reduced libido, which may suggest an underlying hormonal or systemic condition

In line with NICE NG12 guidance, your GP should arrange an urgent two-week-wait referral if you are aged 30 or over with an unexplained breast lump, or an urgent referral if you are aged 50 or over with unilateral nipple changes. Any hard, irregular, or fixed mass, nipple retraction, or swollen lymph nodes in the armpit should also prompt urgent assessment to exclude male breast cancer.

Your GP will typically take a thorough medical and medication history, including any use of supplements or CBD products. They may arrange blood tests to assess hormone levels (testosterone, LH, FSH, oestradiol, prolactin, thyroid function, and human chorionic gonadotrophin [hCG]), as well as liver function tests (LFTs) and renal function, to help identify secondary causes. A testicular examination and, where indicated, a testicular ultrasound may also be arranged to exclude a testicular tumour as an underlying cause. An ultrasound of the breast may be requested if the diagnosis is uncertain.

If you are currently using CBD and suspect it may be contributing to breast changes, do not stop abruptly without speaking to a healthcare professional, particularly if you are using it for a medical reason. Your GP can help weigh the potential benefits and risks and advise on whether discontinuation or a dose adjustment is appropriate.

Safe Use of CBD Products in the UK

The FSA advises healthy adults to take no more than 10 mg of CBD per day from food supplements; always choose third-party tested products, disclose CBD use to your GP, and report unexpected side effects via the MHRA Yellow Card scheme.

Experiencing these side effects? Our pharmacists can help you navigate them →

In the UK, CBD products intended for oral consumption are regulated as novel foods by the Food Standards Agency (FSA). As of 2024, the FSA advises healthy adults to consume no more than 10 mg of CBD per day from food supplements, pending full authorisation. Inclusion on the FSA's public list of validated CBD products allows a product to remain on sale while its safety assessment is ongoing — it does not constitute a safety approval or endorsement. Only products from suppliers who have submitted a valid novel food application should be considered.

The FSA also advises that certain groups should avoid CBD food supplements or seek medical advice before use, including people who are pregnant or breastfeeding, those taking prescribed medicines, and those with liver disease.

To use CBD safely and minimise any potential risk of adverse effects — including any theoretical hormonal effects — consider the following guidance:

• Purchase from reputable suppliers who provide Certificates of Analysis (CoA) from independent, accredited laboratories, confirming CBD content and the absence of harmful contaminants

• Check THC content: choose products with non-detectable or negligible THC levels, as confirmed by a CoA. Under Home Office guidance, CBD products may be sold legally only if they meet the conditions for 'exempt products' under the Misuse of Drugs Regulations 2001 — this is a complex legal area and is not simply a matter of THC being below a fixed consumer threshold. If in doubt, seek products from suppliers who can demonstrate compliance

• Adhere to recommended doses: avoid exceeding the FSA's guidance of 10 mg per day unless under medical supervision

• Disclose CBD use to your GP or pharmacist, particularly if you take prescribed medications. CBD can inhibit cytochrome P450 enzymes and affect the metabolism of a range of medicines, including clobazam, warfarin, and some antiepileptic drugs, as well as other CNS depressants

• Be cautious with unregulated products, including those purchased online from outside the UK, which may not meet safety standards

Whilst CBD is generally considered well-tolerated at low doses, it is not without potential side effects, which can include fatigue, diarrhoea, and changes in appetite. If you experience any unexpected physical changes — including breast tissue alterations — whilst using CBD, report these to your GP and consider reporting them to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk), which helps monitor the safety of medicines and supplements in the UK.

Not sure if this is normal? Chat with one of our pharmacists →

Frequently Asked Questions